Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Shares of Lipocine stock opened at $3.12 on Tuesday. The business has a 50-day simple moving average of $3.31 and a 200-day simple moving average of $4.38. Lipocine has a one year low of $2.75 and a one year high of $11.79. The company has a market cap of $16.69 million, a PE ratio of -4.11 and a beta of 1.51.

Institutional Trading of Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC increased its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. 9.11% of the stock is owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.